Maurizio Averna

Summary

Affiliation: University of Palermo
Country: Italy

Publications

  1. ncbi Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
    Margus Viigimaa
    Tallinn University of Technology, Technomedicum, Ehitajate St, 5, 19086 Tallinn, Estonia
    Lipids Health Dis 9:127. 2010
  2. ncbi Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
    Maurizio Averna
    Professor of Internal Medicine, Department of Clinical Medicine and Emerging Diseases, University of Palermo Medical School, Palermo, Italy
    Diab Vasc Dis Res 8:262-70. 2011
  3. ncbi Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients
    Maurizio Averna
    Department of Clinical Medicine and Emerging Diseases, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy
    J Clin Lipidol 4:272-8. 2010
  4. ncbi Clinical, pathologic, and genetic features of massive soft tissue neurofibromas in a Sicilian patient
    Maria Rita Bongiorno
    Department of Dermatology, University of Palermo, Palermo, Italy
    Dermatol Ther 21:S21-5. 2008
  5. ncbi Clinical utility of novel biomarkers for cardiovascular disease risk stratification
    Maurizio Averna
    Department of Internal Medicine and Medical Specialties DIMIS, University of Palermo, Palermo, Italy
    Intern Emerg Med 7:263-70. 2012
  6. ncbi Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia
    Davide Noto
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo I90127, Italy
    Pediatr Res 67:200-4. 2010
  7. ncbi Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability
    Davide Noto
    Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy
    Clin Chim Acta 328:91-7. 2003
  8. ncbi Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy
    Giuseppina Candore
    Gruppo di Studio sull Immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Universita di Palermo, Palermo, Italy
    Blood Cells Mol Dis 31:57-62. 2003
  9. ncbi Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia
    Davide Noto
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
    Atherosclerosis 206:193-8. 2009

Collaborators

  • Margus Viigimaa
  • Marcello Arca
  • Vilma Mantovani
  • Giuseppina Candore
  • Davide Noto
  • Angelo B Cefalù
  • Francesca Fayer
  • Mariangela Minà
  • Maria Rita Bongiorno
  • Carlo M Barbagallo
  • Anna Montali
  • Francesco Martino
  • Giacoma Barraco
  • Eliana Martino
  • Giuseppe Licata
  • Vincenza Valenti
  • Carmelo Sciume
  • Antonio Pinto
  • Antonino Tuttolomondo
  • Alessandra Cannizzaro
  • Mario Aricò
  • Giovanni Emmanuele
  • Antonio Pace
  • Manfredi Rizzo
  • Giuseppina Marino
  • Alberto Notarbartolo
  • Salvatore Travali

Detail Information

Publications9

  1. ncbi Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency
    Margus Viigimaa
    Tallinn University of Technology, Technomedicum, Ehitajate St, 5, 19086 Tallinn, Estonia
    Lipids Health Dis 9:127. 2010
    ..This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization...
  2. ncbi Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome
    Maurizio Averna
    Professor of Internal Medicine, Department of Clinical Medicine and Emerging Diseases, University of Palermo Medical School, Palermo, Italy
    Diab Vasc Dis Res 8:262-70. 2011
    ..In this post-hoc analysis of high-risk hypercholesterolaemic patients the lipid-reducing effects of ezetimibe/simvastatin or rosuvastatin were not altered significantly by the presence of MetS...
  3. ncbi Ezetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients
    Maurizio Averna
    Department of Clinical Medicine and Emerging Diseases, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy
    J Clin Lipidol 4:272-8. 2010
    ..Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy in patients with hypercholesterolemia and coronary heart disease (CHD)...
  4. ncbi Clinical, pathologic, and genetic features of massive soft tissue neurofibromas in a Sicilian patient
    Maria Rita Bongiorno
    Department of Dermatology, University of Palermo, Palermo, Italy
    Dermatol Ther 21:S21-5. 2008
    ..Among these we identified two heterozygous frameshift mutations in exon 19 (c.2480delA) and a novel mutation in exon 21 (c.2632delC). Ten novel nonsynonymous missense variations were also identified in this patient...
  5. ncbi Clinical utility of novel biomarkers for cardiovascular disease risk stratification
    Maurizio Averna
    Department of Internal Medicine and Medical Specialties DIMIS, University of Palermo, Palermo, Italy
    Intern Emerg Med 7:263-70. 2012
    ..Only few of them had a significant improvement over the predictive models. In this paper, the most investigated biomarkers will be discussed and the evidence of their use as predictors of CV will be questioned...
  6. ncbi Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia
    Davide Noto
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Palermo I90127, Italy
    Pediatr Res 67:200-4. 2010
    ..NCS improve the detection of ADH in pediatric patients, whereas FCHL diagnosis is not improved...
  7. ncbi Differential apolipoprotein(a) isoform expression in heterozygosity is an independent contributor to lipoprotein(a) levels variability
    Davide Noto
    Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy
    Clin Chim Acta 328:91-7. 2003
    ..The individual variability of apolipoprotein(a) isoform expression in heterozygosis could explain part of the lipoprotein(a) levels variability...
  8. ncbi Association between HFE mutations and acute myocardial infarction: a study in patients from Northern and Southern Italy
    Giuseppina Candore
    Gruppo di Studio sull Immunosenescenza, Dipartimento di Biopatologia e Metodologie Biomediche, Universita di Palermo, Palermo, Italy
    Blood Cells Mol Dis 31:57-62. 2003
    ..Thus, our study, performed in two samples of genetically homogeneous patients and controls, does not support the suggestion that HFE mutations may be associated with acute myocardial infarction in susceptible individuals...
  9. ncbi Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia
    Davide Noto
    Department of Clinical Medicine and Emerging Diseases, University of Palermo, Italy
    Atherosclerosis 206:193-8. 2009
    ....